Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2012

View Archived Issues

New phase I data disclosed on KX2-391 in chemotherapy-naive bone-metastatic CRPC

OMP-59R5 well tolerated in phase I study

CalciMedica describes new class of immunomodulators

Clinical studies assess daily and twice-daily dosing of golvatinib

CHMP schedules hearing for Vivus' Qnexa MAA

Novel candidate cancer therapies created at Aurigene Discovery Technologies

Research alliance reached for carfilzomib and oprozomib

Phase III elagolix study begins in endometriosis

MebioPharm set to launch phase II/III MBP-426 trial

Portola Pharmaceuticals presents new SYK inhibitors

Dr. Reddy's Laboratories enters worldwide biosimilars collaboration

PharmaGap provides update on lead program

Roche expands gantenerumab trial in prodromal Alzheimer's disease

Preclinical study validates new target for resistant tumors

Phase I study evaluates peptide vaccine including cancer/testis antigens

Bayer designs novel guanylate cyclase activators

FDA sends complete response letter for ridaforolimus NDA

BioDiem to license new vaccine technology from Australian university

Kythera receives milestone payment from Bayer in ATX-101 collaboration

Research at U.S. university yields new anticancer agents

ProFibrix commences pivotal FINISH-3 study

Starpharma provides enrollment update for pivotal VivaGel studies

AVEO and Astellas planning new phase II study in RCC

Novel protein kinase inhibitors divulged

SDF-1 inhibition may limit transplant vasculopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...